{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T09:18:39Z","timestamp":1782465519366,"version":"3.54.5"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100014848","name":"Arnold Ventures","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s00432-023-04748-5","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T08:01:35Z","timestamp":1683792095000},"page":"9509-9512","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["PARP inhibitors and overall survival in ovarian cancer, reevaluation advised in all settings"],"prefix":"10.1007","volume":"149","author":[{"given":"Timoth\u00e9e","family":"Olivier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,10]]},"reference":[{"key":"4748_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2022-ESGO.488","author":"RL Coleman","year":"2022","unstructured":"Coleman RL, Oza AM, Lorusso D et al (2022) 2022-RA-249-ESGO Overall survival results from ariel3: a phase 3 randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. Int J Gynecol Cancer. https:\/\/doi.org\/10.1136\/ijgc-2022-ESGO.488","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"4748_CR2","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/s41416-018-0271-y","volume":"119","author":"M Friedlander","year":"2018","unstructured":"Friedlander M, Matulonis U, Gourley C et al (2018) Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br J Cancer 119(9):1075\u20131085. https:\/\/doi.org\/10.1038\/s41416-018-0271-y","journal-title":"Br J Cancer"},{"key":"4748_CR3","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1016\/S0090-8258(21)00693-4","volume":"162","author":"U Matulonis","year":"2021","unstructured":"Matulonis U, Herrstedt J, Oza A et al (2021) Long-term safety and secondary efficacy endpoints in the ENGOT-OV16\/NOVA phase III trial of niraparib in recurrent ovarian cancer. Gynecol Oncol 162:S24\u2013S25. https:\/\/doi.org\/10.1016\/S0090-8258(21)00693-4","journal-title":"Gynecol Oncol"},{"key":"4748_CR4","unstructured":"Overall survival results from ARIEL4: A phase III study assessing rucaparib vs chemotherapy in patients with advanced, relapsed ovarian carcinoma and a deleterious BRCA1\/2 mutation (2022). https:\/\/oncologypro.esmo.org\/meeting-resources\/esmo-congress\/overall-survival-results-from-ariel4-a-phase-iii-study-assessing-rucaparib-vs-chemotherapy-in-patients-with-advanced-relapsed-ovarian-carcinoma-a. Accessed 11 Apr 2023"},{"issue":"4","key":"4748_CR5","doi-asserted-by":"publisher","first-page":"e202488","DOI":"10.1001\/jamanetworkopen.2020.2488","volume":"3","author":"S Parsons","year":"2020","unstructured":"Parsons S, Maldonado EB, Prasad V (2020) Comparison of drugs used for adjuvant and metastatic therapy of colon, breast, and non-small cell lung cancers. JAMA Netw Open 3(4):e202488. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.2488","journal-title":"JAMA Netw Open"},{"key":"4748_CR6","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/S0090-8258(22)01244-6","volume":"166","author":"R Penson","year":"2022","unstructured":"Penson R, Valencia RV, Colombo N et al (2022) Final overall survival results from SOLO3: phase III trial assessing olaparib monotherapy versus non-platinum chemotherapy in heavily pretreated patients with germline BRCA1 - and\/or BRCA2-mutated platinum-sensitive relapsed ovarian cancer (026). Gynecol Oncol 166:S19\u2013S20. https:\/\/doi.org\/10.1016\/S0090-8258(22)01244-6","journal-title":"Gynecol Oncol"},{"issue":"15_suppl","key":"4748_CR7","doi-asserted-by":"publisher","first-page":"6002","DOI":"10.1200\/JCO.2020.38.15_suppl.6002","volume":"38","author":"A Poveda","year":"2020","unstructured":"Poveda A, Floquet A, Ledermann JA et al (2020) Final overall survival (OS) results from SOLO2\/ENGOT-ov21: a phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. JCO 38(15_suppl):6002\u20136002. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.6002","journal-title":"JCO"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04748-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-023-04748-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04748-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T20:56:19Z","timestamp":1690491379000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-023-04748-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,10]]},"references-count":7,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["4748"],"URL":"https:\/\/doi.org\/10.1007\/s00432-023-04748-5","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,10]]},"assertion":[{"value":"15 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Vinay Prasad\u2019s disclosures: research funding: Arnold Ventures; royalties: Johns Hopkins Press, Medscape; honoraria: grand rounds\/lectures from universities, medical centers, non-profits, and professional societies; consulting: UnitedHealthcare; speaking fees: Evicore; other: Plenary Session podcast has Patreon backers. Timoth\u00e9e Olivier has no financial nor non-financial conflicts of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Because we used publicly available data, and this is not human subjects\u2019 research in accordance with 45 CFR \u00a746.102(f), we did not submit this study to an institutional review board or require informed consent procedures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not relevant to this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not relevant to this work.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}